For decades, the war on drugs has raged its way across the world, taking a particularly strong hold in America. With politicians from Reagan to Biden fathering policies that have incarcerated millions and killed many more, the world is beginning to see the disastrous effects of drug prohibition. For one thing, it actually can increase deaths from drug overdoses; when Portugal decriminalized all drugs, their addiction and overdose rates plummeted. But another drug, ketamine, offers solutions to the opioid crisis and many other medical problems.
The FDA just approved a new antidepressant, the first of its kind. Unlike other antidepressants, this one is a nasal spray. Esketamine, under the brand name Spravato, is developed by Johnson & Johnson and has been in testing for the past 2 years. The drug has seen remarkable success. This success is interesting because the drug is closely tied to the club drug “Special K.” Related to MDMA, Special K is known as Ecstasy. This marks the first major breakthrough in the treatment of depression since the 1980s.